Preoperative Serum FGF19 in the Prognosis of Biliary Atresia

What this Trial Is About

Researchers are exploring how preoperative levels of serum FGF19 might predict outcomes for children with biliary atresia, a serious liver condition. The study focuses on children who have undergone Kasai portoenterostomy, a common surgery for this condition. Since about 30% of these children may still need a liver transplant after surgery, finding accurate ways to predict prognosis before surgery is important. This research aims to confirm the value of serum FGF19 as a predictive marker in a large group of Asian children. The study observes children diagnosed with biliary atresia who have had the Kasai surgery. It classifies their prognosis into two groups based on serum total bilirubin levels measured three months after surgery and liver transplant or survival status at one year. A good prognosis means bilirubin is less than 20 umol/l and no transplant or death within a year; a poor prognosis means bilirubin is higher than 20 umol/l without transplant or death in that time. Researchers collect and analyze preoperative serum samples and follow patients for one year. Participants will have their clinical data and serum bilirubin levels recorded three months after surgery, followed by monitoring their liver survival status for one year. The study measures serum total bilirubin levels and native liver survival as primary outcomes. Data collection involves reviewing preoperative serum samples and follow-up records. Children with biliary atresia and available surgical and follow-up data will be included, with no specific age restrictions. The study is conducted by the Children's Hospital of Fudan University and will continue until August 2027.

Preoperative Serum FGF19 in the Prognosis of Biliary Atresia